ACSQHC-ARCR-403

The Australian Particle Therapy Clinical Quality Registry (ASPIRE) was initiated to collect participant data to describe the patterns of care for patients receiving conventional Xray therapy (Photon) versus Proton Beam therapy (PBT) as part of ongoing government funding of PBT. Current Medicare Benefits Schedule (MBS) items exist for some paediatric, adolescent and rare adult tumours to be treated with PBT. A lack of evidence reporting the long-term side effects of photon versus PBT means there is a recognised disparity in equity of access to PBT for other tumour types. The ASPIRE registry is a prospective, observational, longitudinal study of paediatric, adolescent, young adult (AYA) and rare adult tumour patients from a select group of tumour streams treated with radiotherapy, being those that are in the MBS approved list. The primary objective of the registry is to describe the long-term effects and disease control outcomes with a specific focus on side effects patients experience from their radiation treatment and the economic savings by improving radiotherapy side effects.